Compare Adaptive Biotechnologies Corp (ADPT) vs NetFlix Inc (NFLX) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Netflix (NFLX) trades at $76.02, down 2.1% amid a bearish technical trend, though fundamentals remain strong with 2025 revenue of $45.18B and net income of $10.98B. The stock is near its 52-week low, with support at $75 and resistance at $77. Recent Q1 2026 earnings beat expectations with EPS of $1.23 versus $0.76 expected, highlighting robust operational performance despite market pessimism.

The outlook is mixed: strong fundamentals and a consensus price target of $114.75 suggest 51% upside, but technical weakness and competitive pressures pose risks. Investors should weigh the company's high ROE of 48.5% and scaling ad business against market sentiment and recent stock declines.